SAb Biotherapeutics logo
  • About Us
    • Company Profile
    • Senior Management
    • Board of Directors
    • Clinical Advisory Board
  • Our Pipeline
  • Our Science
  • For Patients
  • Investors & Media
    • Overview
    • News & Press Releases
    • Presentations
    • Publications
    • Events
    • SEC Filings
    • Stock Quote & Chart
    • Senior Management
    • Board of Directors
    • Board Committees
    • Corporate Governance
    • Clinical Advisory Board
    • Analyst Coverage
    • RSS Feeds
    • Contact Us
  • Careers
  • Contact Us
  • About Us
    • Company Profile
    • Senior Management
    • Board of Directors
    • Clinical Advisory Board
  • Our Pipeline
  • Our Science
  • For Patients
  • Investors & Media
    • Overview
    • News & Press Releases
    • Presentations
    • Publications
    • Events
    • SEC Filings
    • Stock Quote & Chart
    • Senior Management
    • Board of Directors
    • Board Committees
    • Corporate Governance
    • Clinical Advisory Board
    • Analyst Coverage
    • RSS Feeds
    • Contact Us
  • Careers
  • Contact Us
Home > Press Release
All | News | Press Release | Events
SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza

July 30, 2020

SAB Biotherapeutics Closes Series B Funding

July 17, 2020
SAB Biotherapeutics President And CEO Eddie J. Sullivan, PhD, Featured On COVID-19 Panel At BIO Digital 2020

SAB Biotherapeutics President And CEO Eddie J. Sullivan, PhD, Featured On COVID-19 Panel At BIO Digital 2020

June 8, 2020
SAB Biotherapeutics Confirms Neutralizing Antibodies To SARS-CoV-2 And Begins Clinical Manufacturing Of Novel COVID-19 Therapeutic Candidate

SAB Biotherapeutics Confirms Neutralizing Antibodies To SARS-CoV-2 And Begins Clinical Manufacturing Of Novel COVID-19 Therapeutic Candidate

May 28, 2020
SAB Biotherapeutics Advances Therapeutic For COVID-19 In Partnership With Department Of Defense And BARDA

SAB Biotherapeutics Advances Therapeutic For COVID-19 In Partnership With Department Of Defense And BARDA

April 16, 2020
CSL Behring And SAB Biotherapeutics Join Forces To Deliver New Potential COVID-19 Therapeutic

CSL Behring And SAB Biotherapeutics Join Forces To Deliver New Potential COVID-19 Therapeutic

April 8, 2020
SAB Biotherapeutics Awarded $27M Contract  to Develop Novel Rapid Response Capability for U.S. Department of Defense

SAB Biotherapeutics Awarded $27M Contract to Develop Novel Rapid Response Capability for U.S. Department of Defense

March 31, 2020
SAB Biotherapeutics Delays Development At USD Discovery District

SAB Biotherapeutics Delays Development At USD Discovery District

March 13, 2020
SAB Biotherapeutics Announces Research Collaboration With CSL Behring

SAB Biotherapeutics Announces Research Collaboration With CSL Behring

January 7, 2020

SAB Biotherapeutics Raises $22M In Series A-2 Round

December 20, 2018
South Dakota Equity Partners Invests $1.05M In SAB Biotherapeutics

South Dakota Equity Partners Invests $1.05M In SAB Biotherapeutics

December 18, 2018
USD Discovery District Breaks Ground For First Building Project

USD Discovery District Breaks Ground For First Building Project

November 20, 2018
Previous Next
SAb Biotherapeutics logo
  • ©2025 SAb Biotherapeutics, Inc.
  • All Rights Reserved
  • Terms & Conditions
  • Privacy Policy
  • Conflict of Interest Policy
  • Contact Us